References
- global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease2018 Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdfAccessed October 11, 2018
- SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med201414117825404569
- D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res201415112325756831
- BeierJKirstenA-MMrózREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIB studyCOPD201310451152223819698
- JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
- KonSSCCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
- MocarskiMZaiserETrundellDMakeBJHareendranAEvaluation of the psychometric properties of the Nighttime Symptoms of COPD InstrumentInt J Chron Obstruct Pulmon Dis20151047548725834415
- HareendranAMakeBJZaiserEGarcia GilEEvaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI)Int J Chron Obstruct Pulmon Dis2018131633164529849455
- LeidyNKMurrayLTMonzBUMeasuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trialsRespir Res201415112425287629
- DonohueJFSoongWWuXShresthaPLeiALong-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPDRespir Med2016116414827296819
- D’UrzoARennardSKerwinEA randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary diseaseRespir Med2017125394828340861
- CalverleyPMALeeATowseLvan NoordJWitekTJKelsenSEffect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary diseaseThorax2003581085586014514937
- VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J20164841030103927492833
- BatemanEDChapmanKRSinghDAclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multi-centre, randomised studies (ACLIFORM and AUGMENT)Respir Res20151619226233481
- WatzHTroostersTBeehKMACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPDInt J Chron Obstruct Pulmon Dis2017122545255828883722
- DemeyerHBurtinCHornikxMThe minimal important difference in physical activity in patients with COPDPLoS One2016114e015458727124297
- BattistiWPWagerEBaltzerLGood publication practice for communicating company-sponsored medical research: GPP3Ann Intern Med2015163646146426259067